Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ZNF117 target ChIP-seq

ABSTRACT: ZNF117 target ChIP-seq

PROVIDER: PRJNA803202 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17873558.fastq.gz	Fastqsanger.gz
	SRR17873559.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Identification of ChIP-seq and RIME grade antibodies for Estrogen Receptor alpha

Project description:Estrogen Receptor alpha (ERα) is a key driver of most breast cancers, and it is the target of endocrine therapies used in the clinic to treat women with ERα positive (ER+) breast cancer. The two methods ChIP-seq (chromatin immunoprecipitation coupled with deep sequencing) and RIME (Rapid Immunoprecipitation of Endogenous Proteins) have greatly improved our understanding of ERα function during breast cancer progression and in response to anti-estrogens. A critical component of both ChIP-seq and RIME protocols is the antibody that is used to pull down the bait protein. To date, most of the ChIP-seq and RIME experiments for the study of ERα have been performed using the sc-543 antibody from Santa Cruz Biotechnology. However, this antibody has been discontinued, thereby severely impacting the study of ERα in normal physiology as well as diseases such as breast cancer and ovarian cancer. Here, we compare the sc-543 antibody with other commercially available antibodies, and we show that 06-935 (EMD Millipore) and ab3575 (Abcam) antibodies can successfully replace the sc-543 antibody for ChIP-seq and RIME experiments.

2019-03-21 | PXD012930 | Pride

MGA represses MYC-target genes [ChIP-seq]

Project description:MGA represses MYC-target genes [ChIP-seq]

| PRJNA445195 | ENA

ChIP-Seq analysis of PAX6A and PAX6D target genes

Project description:ChIP-Seq analysis of PAX6A and PAX6D target genes

| PRJNA526530 | ENA

Elucidation of FOXP1 target genes in DLBCL by ChIP-Seq

Project description:Elucidation of FOXP1 target genes in DLBCL by ChIP-Seq

| PRJEB9851 | ENA

ChIP-seq data were used to analyze ASR3 target genes

Project description:ChIP-seq data were used to analyze ASR3 target genes

| PRJNA812914 | ENA

The identification of Stat92E target genes in Drosophila testis by ChIP-seq [Stat-ChIP]

Project description:The identification of Stat92E target genes in Drosophila testis by ChIP-seq [Stat-ChIP]

| PRJNA1008836 | ENA

The identification of Stat92E target genes in Drosophila testis by ChIP-seq [CG-ChIP]

Project description:The identification of Stat92E target genes in Drosophila testis by ChIP-seq [CG-ChIP]

| PRJNA1008837 | ENA

Identification of Angustifolia 3 (ZmAN3) target genes through GSyellow-based ChIP-seq in Zea mays leaves

Project description:Genome-wide target genes of ZmAN3 were identified through ChIP-seq on the growth zone of the maize leaf, encompassing the division, transition and expansion zone. For ChIP-seq, ZmAN3 was fused to the GSyellow TAP tag and expressed from the ubiquitin promoter (pUBIL). The pUBIL:ZmAN3-GSyellow construct was transformed into the maize inbred line B104. ChIP was performed using anti-GFP antibody (abcam290).

2018-08-07 | E-MTAB-6527 | biostudies-arrayexpress

Direct ChIP-Seq significance analysis improves target prediction.

Project description:Chromatin immunoprecipitation followed by sequencing of protein-bound DNA fragments (ChIP-Seq) is an effective high-throughput methodology for the identification of context specific DNA fragments that are bound by specific proteins in vivo. Despite significant progress in the bioinformatics analysis of this genome-scale data, a number of challenges remain as technology-dependent biases, including variable target accessibility and mappability, sequence-dependent variability, and non-specific binding affinity must be accounted for.We introduce a nonparametric method for scoring consensus regions of aligned immunoprecipitated DNA fragments when appropriate control experiments are available. Our method uses local models for null binding; these are necessary because binding prediction scores based on global models alone fail to properly account for specialized features of genomic regions and chance pull downs of specific DNA fragments, thus disproportionally rewarding some genomic regions and decreasing prediction accuracy. We make no assumptions about the structure or amplitude of bound peaks, yet we show that our method outperforms leading methods developed using either global or local null hypothesis models for random binding. We test prediction performance by comparing analyses of ChIP-seq, ChIP-chip, motif-based binding-site prediction, and shRNA assays, showing high reproducibility, binding-site enrichment in predicted target regions, and functional regulation of predicted targets.Given appropriate controls, a direct nonparametric method for identifying transcription-factor targets from ChIP-Seq assays may lead to both higher sensitivity and higher specificity, and should be preferred or used in conjunction with methods that use parametric models for null binding.

| S-EPMC4460594 | biostudies-literature

Anti-cancer drugs curaxins target the 3D genome organization [ChIP-seq]

Project description:Anti-cancer drugs curaxins target the 3D genome organization [ChIP-seq]

| PRJNA505308 | ENA